3 min read

Ten Reasons to Plan Early and Conduct Post-Marketing Research

Post-marketing challenges require strategic and innovative solutions for continued safety surveillance and demonstrating value and effectiveness.
Read about the solutions for continued surveillance of product safety and for demonstrating value and effectiveness based on real-world evidence.

Manufacturers of biopharmaceutical products and medical devices understand that the regulatory approval of their product will bring postmarketing challenges, requiring strategic and innovative solutions for continued surveillance of product safety and for demonstrating value and effectiveness based on real world evidence.

It is important that such evidence requirements are well understood and a strategic evidence gathering plan is in place even before product approval. UBC has compiled a list of reasons to begin planning pre-marketing and to conduct postmarketing research with the aim of demonstrating product value.

1. Disease natural history: Understand the characteristics of patients with the disease before product approval and evaluate the impact of a product in the overall treatment regimen once marketed.

2. Health services research: Understand the impact that health systems, plans, and provider organizations have on the delivery and outcomes of healthcare. Research payer priorities and address in studies.

3. Real-world effectiveness: Observe and document real world effectiveness in contrast to the efficacy measures documented in clinical trials.

4. Comparative effectiveness: Determine how a new product compares with the current “standard of care,” or with other competitors’ products in clinical practice.

5. Patient-reported outcomes: Evaluate patient (and/or caregiver) reported outcomes to inform or support market access, including health-related quality of life, impact of disease and treatment, satisfaction with treatment, and adherence.

6. Cost of care implications: Collect resource utilization and other relevant data to quantify the burden of illness and economic impact of disease and recognize how savings may be realized through alternative therapies. Measure and assess the differential economic impact of a novel product versus an alternative intervention or other healthcare service.

7. Prescriber and patient preferences: Identify the decision-making process related to reasons why prescribers and/or patients prefer certain treatment characteristics and why patients adhere (or not!) to prescribed medications.

8. Safety: Gather data on the adverse effects of a product versus other standard of care treatments as they are used in real-world populations.

9. Disease and patient heterogeneity: Understand how conditions, including orphan diseases, vary in terms of presentation and progression over time. Patients treated in actual clinical practice are considerably more varied than those included in clinical trials.

10. Longitudinal outcomes: Increase the duration of follow-up to better understand effectiveness and safety, cost, and patient-reported outcomes or to evaluate outcomes with long latency.

Planning can begin as soon as late Phase II or the beginning of Phase III to document disease natural history and the impact of the current standard of care and to understand payer priorities.

Interested in learning more about how postmarketing research can help document the ongoing value of your product?  Contact us.

Other Recent Posts

Press
5 min read

UBC Successfully Implemented REMS Administration Software DuringHL7® FHIR® Connectathon

UBC demonstrated our commitment to optimizing safe medication use and health outcomes by participating in the HL7® FHIR® Connectathon.
Press
5 min read

UBC Selects Oracle Cloud Safety Technology for its Safety Programs

UBC selected Oracle Life Sciences' safety case management solution.
Press
2 min read

UBC Receives CRO Leadership Award Again

UBC was honored as a winner in the 2023 CRO Leadership Awards by both big and small pharma in the Reliability category.

Thank You for Connecting with UBC

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

What You Can Expect Next

Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.

Get Ready to Change Your Business

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

Service Request

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.